Sijie Lu, B.S., Ph.D.
Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine
About Dr. Sijie Lu
I received my Ph.D. from Michigan State University in 1994. I continued my research career as an NIH postdoctoral fellow at Baylor College of Medicine from 1994 to 2000 in the lab of Dr. Adam Kuspa, who specialized in molecular genetics I joined the faculty at The University of Texas M. D. Anderson Cancer Center in December of 2000 as an Instructor in the Stem Cell Transplantation and Cellular Therapy Department and promoted to Assistant Professor in September of 2004. Since joining MDACC, I have been a member of the Transplantation Immunology Section.
Read More
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Hematopoietic Biology and Malignancy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
One of our interests in the lab is discovering leukemia-associated antigens (LAA), which is the first step towards separating beneficial graft versus leukemia (GvL) effect from the detrimental graft versus host disease (GvHD). We have focused on Myeloperoxidase (MPO), which is overexpressed in 50% of AML, 75% of CML , and 30% of MDS patients. We have identified two novel, HLA-A2-restricted peptides, MY4 and MY8, as leukemia-associated antigens. We have been able to elicit MY4- and MY8-specific cytotoxic T cells (CTL) from healthy donor’s peripheral blood mononuclear cells (PBMC). These CTLs have shown the capability to kill leukemic cells but not normal bone marrow in vitro. In addition, these CTLs can drastically reduce tumor burden (50-70%) in vivo when co-injected with leukemic cells in an immune-compromised mouse. These data suggest that both MY4 and MY8 could be used as immunotherapy reagents, such as vaccines, for treating leukemia
Education & Training
Degree-Granting Education
| 1994 | Michigan State University, East Lansing, Michigan, US, Biochemistry, Ph.D |
| 1988 | Peking University, Beijing, CN, Biochemistry, BS |
Postgraduate Training
| 1995-1997 | National Institutes of Health, Postdoctoral Fellow, Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas |
| 1988-1994 | Predoctoral student, Michigan State University, East Lansing, Michigan |
| 1977-1988 | Undergraduate research student, Mei-hua Liu, Peking University, Beijing |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Stem Cell Transplantation - Research, UT M. D. Anderson Cancer Center, Houston, TX, 2004 - 2020
Instructor, Department of Stem Cell Transplantation - Research, UT M. D. Anderson Cancer Center, Houston, TX, 2000 - 2004
Research Associate, Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, 1997 - 2000
Other Professional Positions
Lab Coordinator, Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, UT M. D. Anderson Cancer Center, Houston, TX, 2000 - Present
Honors & Awards
| 2004 | Fujisawa New Investigator Award, American Society for Blood and Marrow Transplantation (ASBMT) |
| 1995 - 1997 | NIH National Research Service Award, Baylor College of Medicine |
| 1992 | College of Natural Science Graduate Fellowship for Excellence in Research, Michigan State University |
| 1985 | Award for Excellence in Academic Achievement for Undergraduate Students, Peking University |
Selected Presentations & Talks
Local Presentations
- 2014. Bi-specific T-cell Engaging Antibody Activates T-cells to Target the Tumor Associated Antigen PR1 (Poster). Conference. Bi-specific T-cell Engaging Antibody Activates T-cells to Target the Tumor Associated Antigen PR1 (Poster). Houston, TX, US.
- 2008. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Conference. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Houston, TX, US.
- 2005. Myeloperoxidase as a leukemia-associated antigen. Conference. Myeloperoxidase as a leukemia-associated antigen. Houston, TX, US.
- 2004. Adoptive cellular immunotherapy of leukemia. Conference. Adoptive cellular immunotherapy of leukemia. Houston, TX, US.
- 1995. Genetic analysis of signal transduction in dictyostelium development. Conference. Genetic analysis of signal transduction in dictyostelium development. Houston, TX, US.
Regional Presentations
- 2014. A TCR-like chimeric antigen receptor (CAR) against the PR1/HLA-A2 complex rapidly reduces leukemia in vivo. Conference. A TCR-like chimeric antigen receptor (CAR) against the PR1/HLA-A2 complex rapidly reduces leukemia in vivo. Montgomery, TX, US.
- 2004. Adoptive cellular immunotherapy of leukemia. Conference. Adoptive cellular immunotherapy of leukemia. San Diego, CA, US.
National Presentations
- 2022. Humanized T cell receptor-like antibody Hu8F4 reduces leukemia by Fc-mediated mechanism (poster, abstract #4081). Poster. 64th American Society of Hematology Annual Meeting, US.
- 2022. A novel approach to reduce cytotoxicity and preserve efficacy of chimeric antigen receptor T cells fpr adoptive transfer (poster, abstract #1984). Poster. 64th American Society of Hematology Annual Meeting. New Orleans, LA, US.
- 2008. Genomics as a tool for antigen discovery in allogeneic stem cell transplantation: Identification of the minor antigen T4A through donor/patient polymorphism disparities (Poster, Abstract #3907). Conference. 50th American Society of Hematology Annual Meeting. San Francisco, CA, US.
- 2008. Direct visualization of PR1/HLA-A2 on the membrane of HLA-A2+CD13+CD33+ myeloid leukemia blasts by a novel monoclonal antibody (Poster, Abstract #2545). Conference. 50th American Society of Hematology Annual Meeting. San Francisco, CA, US.
- 2005. High avidity cyclin E-derived peptide-specific CTL contribute to induction of remission after stem cell transplantation without associated graft-versus-host disease (Poster, Abstract #1424). Conference. 47th American Society of Hematology Annual Meeting. Atlanta, GA, US.
- 2005. PR1 leukemia-associated antigen is cross-presented by B cells from soluble serum proteases (Poster, Abstract #2397). Conference. 47th American Society of Hematology Annual Meeting. Atlanta, GA, US.
- 2005. High avidity cyclin E1-derived peptide-specific CTL kill lymphoid leukemia cells and cross-recognize a homologous cyclin E2-derived peptide (Poster). Conference. 2005 Tandem Blood and Marrow Transplantation Annual Meeting. Keystone, CO, US.
- 2004. Antigen cross-presentation allows the PR1 leukemia-associated antigen to be processed from both proteinase 3 and neutrophil elastase to prime T cells (Poster, Abstract #3245). Conference. 46th American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2003. PR1 peptide vaccination of myeloid leukemia patients induces PR1-specific CTL with high CCR7 expression (Poster, Abstract #2257). Conference. 45th American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2003. Cyclin E2 peptide-specific CTL clone shows cross recognition of a homologous cyclin E1 peptide and kills lymphoid and myeloid leukemia cells (Poster, Abstract #2595). Conference. 45th American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2003. The PR1 leukemia-associated antigen is endogeneously processed and presented from both proteinase 3 and neutrophil elastase and is recognized by T lymphocytes (Poster, Abstract #2571). Conference. 45th American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2003. The leukemia-associated antigen PR1 is derived from both proteinase 3 and neutrophil elastase proteins (Poster, Abstract #92). Conference. 2003 Tandem Blood and Marrow Transplantation Annual Meeting. Keystone, CO, US.
- 2001. Effective specific immunity induced after PR1 peptide vaccination correlates with cytogenetic remission (Poster, Abstract #1708). Conference. 43rd American Society of Hematology Annual Meeting. Orlando, FL, US.
- 2001. Induction of high affinity allogeneic PR1-specific CTL response is associated with cytogenetic remission after PR1 peptide vaccine (Poster, Abstract #2735). Conference. 43rd American Society of Hematology Annual Meeting. Orlando, FL, US.
International Presentations
- 2004. Myeloperoxidase as a leukemia-associated antigen. Conference. 10th Society of Chinese Bioscientists in America International Symposium. Beijing, CN.
- 1992. Role of sK RNA polymerase and SpoIIID protein in mother-cell gene regulation. Conference. 11th International Spores Conference. Woods Hole, US.
Grant & Contract Support
| Date: | 2023 - 2025 |
| Title: | Enhancing CAR T Cell Homing Through Glycoengineering |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R21CA270491-01 |
| Date: | 2018 - 2023 |
| Title: | Novel Cord Blood Derived Cellular Therapies |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | 2-P01-CA148600-07-A1 |
| Date: | 2015 - 2020 |
| Title: | Physical Dynamics of the Tumor-Host Ecosystem |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2014 - 2019 |
| Title: | AML/MDS Moon Shot Program, Flagship 2 Subproject |
| Funding Source: | M. D. Anderson Moon Shots |
| Role: | Collaborator |
| Date: | 2011 - 2017 |
| Title: | Improving Cord Blood Transplantation (PP-4) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5-PO1-CA148600-05 |
| Date: | 2011 - 2016 |
| Title: | The Therapy of CML, GMP & Immune Assessment Core |
| Funding Source: | NIH/NCI |
| Role: | Faculty Collaborator |
| ID: | 5-P01-CA049639-24 (PC-E) |
| Date: | 2006 - 2011 |
| Title: | Cyclin E-Derived Peptides as Targest of CTL-Mediated Immunity Against Leukemia |
| Funding Source: | Gillson-Longenbaugh Foundation |
| Role: | Co-I |
| ID: | 9091.001-G 2007-03 |
| Date: | 2004 - 2006 |
| Title: | Selective Expansion of Anti-Leukemic CTL for Donor Lymphocyte Infusion |
| Funding Source: | American Society for Blood and Marrow Transplantation (ASBMT) |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- He, H, Vedia, RA, Lu, S, Li, Q, Cox, K, St John, L, Sergueeva, A, Dwyer, KC, Al-Atrash, G, Shpall, E, Ma, Q, Molldrem, JJ. Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo. Cytotherapy 26(11):1331-1340, 2024. e-Pub 2024. PMID: 39033444.
- Molldrem J, He H, Vedia R, Lu S, Li Q, Cox K, St John L, Sergeeva A, Clise-Dwyer K, Alatrash G, Shpall E, Ma Q. Hu8F4-CAR T cells with mutated Fc spacer segment improve target-specificity and mediate anti-leukemia activity in vivo. Res Sq, 2024. e-Pub 2024. PMID: 38464203.
- Lu S, Tallis E, Ding X, Li D, Cox K, You MJ, St John L, Alatrash G, Ma Q, Molldrem JJ. Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia. Cytotherapy 23(9):793-798, 2021. e-Pub 2021. PMID: 34215503.
- He H, Kondo Y, Ishiyama K, Alatrash G, Lu S, Cox K, Qiao N, Clise-Dwyer K, St John L, Sukhumalchandra P, Ma Q, Molldrem JJ. Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia. Leukemia 34(6):1626-1636, 2020. e-Pub 2020. PMID: 31908357.
- Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia R, Sergeeva A, Yi S, Young KH, Philips AV, Cernosek AM, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ. Targeting the Leukemia Antigen PR1 with Immunotherapy for the treatment of Multiple Myeloma. Clin Cancer Res 24(14):3386-3396, 2018. e-Pub 2018. PMID: 29661776.
- Herrmann AC, Im JS, Pareek S, Ruiz-Vasquez W, Lu S, Sergeeva A, Mehrens J, He H, Alatrash G, Sukhumalchandra P, St John L, Clise-Dwyer K, Zha D, Molldrem JJ. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2. Front Immunol 9:3153, 2018. e-Pub 2018. PMID: 30713535.
- Kerros C, Tripathi SC, Zha D, Mehrens JM, Sergeeva A, Philips AV, Qiao N, Peters HL, Katayama H, Sukhumalchandra P, Ruisaard KE, Perakis AA, St John LS, Lu S, Mittendorf EA, Clise-Dwyer K, Herrmann AC, Alatrash G, Toniatti C, Hanash SM, Ma Q, Molldrem JJ. Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells. J Biol Chem 292(24):10295-10305, 2017. e-Pub 2017. PMID: 28468826.
- Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31(3):697-704, 2017. e-Pub 2017. PMID: 27654852.
- Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy 18(8):985-94, 2016. e-Pub 2016. PMID: 27265873.
- Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G. A Novel HLA-A*0201 Restricted Peptide Derived from Cathepsin G Is an Effective Immunotherapeutic Target in Acute Myeloid Leukemia. Clin Cancer Res 19(1):247-57, 2013. e-Pub 2013. PMID: 23147993.
- Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ. Broad Cross-Presentation of the Hematopoietically Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy. J Immunol 189(11):5476-84, 2012. e-Pub 2012. PMID: 23105141.
- Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res 72(13):3153-62, 2012. e-Pub 2012. PMID: 22564522.
- Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, Wieder ED, Lizee G, Lu S, Molldrem JJ. The Role of Antigen Cross-presentation From Leukemia Blasts on Immunity to the Leukemia-associated Antigen PR1. J Immunother 35(4):309-20, 2012. e-Pub 2012. PMID: 22495388.
- Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, McIntyre BW, Ma Q, Li D, St John L, Clise-Dwyer K, Molldrem JJ. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 117(16):4262-72, 2011. e-Pub 2011. PMID: 21296998.
- Armistead PM, Liang S, Li H, Lu S, Van Bergen CA, Alatrash G, St John L, Hunsucker SA, Sarantopoulos S, Falkenburg JH, Molldrem JJ. Common Minor Histocompatibility Antigen Discovery Based upon Patient Clinical Outcomes and Genomic Data. PLoS One 6(8):e23217, 2011. e-Pub 2011. PMID: 21858034.
- Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y, Wieder ED, Clise-Dwyer K, Alatrash G, Mj Y, Munsell MF, Lu S, Qazilbash MH, Molldrem JJ. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 12(8):1056-62, 2010. e-Pub 2010. PMID: 20735170.
- Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, Clise-Dwyer K, Molldrem JJ. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One 5(7):e11770, 2010. e-Pub 2010. PMID: 20668669.
- Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5):787-98, 2009. e-Pub 2009. PMID: 19879162.
- Wang Y, Li D, Nurieva R, Yang J, Sen M, Carreño R, Lu S, McIntyre BW, Molldrem JJ, Legge GB, Ma Q. LFA-1 affinity regulation is necessary for the activation and proliferation of naive T cells. J Biol Chem 284(19):12645-53, 2009. e-Pub 2009. PMID: 19297325.
- Liu X, Alexiou M, Martin-Orozco N, Chung Y, Nurieva RI, Ma L, Tian Q, Kollias G, Lu S, Graf D, Dong C. Cutting edge: A critical role of B and T lymphocyte attenuator in periperal T cell tolerance induction. J Immunol 182(8):4516-20, 2009. e-Pub 2009. PMID: 19342624.
- Knuth M, Khaire N, Kuspa A, Lu S, Schleicher M, Noegel A. A novel partner for dictyostelium filamin is an a-helical developmentally regulated protein. Journal of Science 117:5013-5022, 2004. e-Pub 2004. PMID: 15383615.
- Maeda M, Lu S, Shaulsky G, Miyazaki Y, Kuwayama H, Tanaka Y, Kuspa A, Loomis WF. Periodic signaling controlled by an oscillatory circuit that includes protein kinases ERK2 and PKA. Science 304(5672):875-8, 2004. e-Pub 2004. PMID: 15131307.
- Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 111(5):639-47, 2003. e-Pub 2003. PMID: 12618518.
- Molldrem JJ, Kant S, Jiang W, Lu S. The basis of T-cell-mediated immunity to chronic myelogenous leukemia. Oncogene 21(56):8668-73, 2002. e-Pub 2002. PMID: 12476312.
- Wessels DJ, Zhang H, Reynolds J, Daniels K, Heid P, Lu S, Kuspa A, Shaulsky G, Loomis WF, Soll DR. The internal phosphodiesterase RegA is essential for the suppression of lateral pseudopods during Dictyostelium chemotaxis. Mol Biol Cell 11(8):2803-20, 2000. e-Pub 2000. PMID: 10930471.
- Souza GM, Lu S, Kuspa A. YakA, a protein kinase required for the transition from growth to development in Dictyostelium. Development 125(12):2291-302, 1998. e-Pub 1998. PMID: 9584128.
- Carlson HC, Lu S, Kroos L, Haldenwang WG. Exchange of precursor-specific elements between pro-sigma E and pro-sigma K of Bacillus subtilis. J Bacteriol 178(2):546-9, 1996. e-Pub 1996. PMID: 8550479.
- Lu S, Cutting S, Kroos L. Sporulation protein SpoIVFB from bacillus subtilis enhances processing of the sigma factor precursor Pro-sigma K in the absence of other sporulation gene products. J Bacteriol 177(4):1082-5, 1995. e-Pub 1995. PMID: 7860587.
- Lu S, Kroos L. Overproducing the bacillus subtilis mother cell sigma factor precursor, Pro-sigma K, uncouples sigma K-dependent gene expression from dependence on intercompartmental communication. J Bacteriol 176(13):3936-43, 1994. e-Pub 1994. PMID: 8021176.
- Cutting S, Oke V, Driks A, Losick R, Lu S, Kroos L. A forespore checkpoint for mother cell gene expression during development in B. subtilis. Cell 62(2):239-50, 1990. e-Pub 1990. PMID: 2115401.
- Lu S, Halberg R, Kroos L. Processing of the mother-cell sigma factor, sigma K, may depend on events occurring in the forespore during Bacillus subtilis development. Proc Natl Acad Sci U S A 87(24):9722-6, 1990. e-Pub 1990. PMID: 2124700.
Invited Articles
- Lu S, Wieder E, Komanduri K, Ma Q, Molldrem JJ. Vaccines in leukemia. Adv Pharmacol 51:255-70, 2004. e-Pub 2004. PMID: 15464913.
Editorials
- Molldrem JJ, Lu S. A GVHD Kill Switch Helps Immune Reconstitution. Blood 123(25):3849-50, 2014. PMID: 24948621.
Abstracts
- Herrmann A, Im J, Lu S, Sergeeva A, Molldrem JJ. Development of a novel TCR-like Bi-specific T cell engager targeting PR1/HLA-A2 leukemia antigen. AACR 107th Annual Meeting 2016, 2016. e-Pub 2016.
- Alatrash G, Zhang M, Sukhumalchandra P, Qiu Y, Talukder AH, Senyukov V, St John LS, He H, Sergeeva A, Roszik J, Dwyer KC, Lu S, Ma Q, Mittendorf EA, Lee D, Hawke DH, Lizee G, Molldrem JJ, Kornblau SM. Cathepsin G Is Broadly Expressed By AML and Is an Effective Immunotherapeutic Target Against AML in Vivo. Blood (Poster Session) 124(21), 2014. e-Pub 2014.
- Alatrash G, Sukhumalchandra P, Zhang M, Kerros C, Sergeeva A, Cernosek A, Jakher H, Zope M, Patenia R, St John L, Perakis A, Dwyer KC, Young KH, Weng J, Lu S, Mittendorf EA, Kwak LW, Ma Q, Molldrem JJ. PR1 Is Cross-Presented By Multiple Myeloma Cells in Patients and Renders Multiple Myeloma Susceptible to PR1-CTL and Anti-PR1/HLA-A2 Antibody. Blood (Poster Session) 124(21), 2014. e-Pub 2014.
- Jin I, Cernosek A, Sergeeva A, Molldrem JJ, Lu S. Novel TCR-like Bi-Specific T Cell Engaging Antibody Targeting the PR1/HLA-A2 Myeloid Leukemia Antigen. Blood (Poster Session) 124(21), 2014. e-Pub 2014.
- Herrmann A, Im JS, Lu S, Molldrem JJ. Bi-specific T-cell engaging antibody activates T-cells to target the tumor associated antigen PR1. American Association for Cancer Research Annual Proceedings, 2014. e-Pub 2014.
- St John L, Clise-Dwyer K, Patenia R, Sergeeva A, He H, Bollard C, Shpall E, Lu S, Ma Q, Molldrem J. A High Frequency of Naive PR1-specific CD8+ T Cells in Umbilical Cord Blood and Fetal Thymus Suggest Incomplete Central Tolerance to the Hematopoietic Self-antigen PR1. The Journal of Immunology 188, 2013. e-Pub 2013.
- Vincent BG, Singh D, Wu M, Hunsucker SA, Alatrash G, Ruisaard K, Sukhumalchandra P, Clise-Dwyer K, Serody JS, Prins JF, Molldrem JJ, Armistead PM. RNA-Seq Expression Profiling of AML Stem Cells Reveals Differential Expression of Lineage Differentiation Markers and Novel Splice Variants. Blood (Poster Session), 2012. e-Pub 2012.
- Yang TH, Clise-Dwyer K, St John LS, Alatrash G, Ruisaard K, Lu S, Molldrem JJ. Membrane-Associated Proteinase 3 on Granulocytes and Myeloid Leukemia Mediates Reversible Inhibition of T Cell Proliferation Associated with Altered ZAP70 and ERK Signaling. Blood (Poster Session), 2012. e-Pub 2012.
- Alatrash G, Sukhumalchandra P, Zhang M, Sergeeva A, Jakher H, Weng J, St John LS, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ. Multiple Myeloma Cross-Presents Neutrophil Elastase and Proteinase 3 and Becomes Susceptible to PR1-Targeting Immunotherapy. Blood (Online Publication), 2012. e-Pub 2012.
- Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Ruisaard K, Al Atrache Z, Ropp PA, Rodriguez-Cruz T, Mittendorf E, Lizee G, Clise-Dwyer K, Lu S, Glish GL, Molldrem JJ, Armistead PM, Alatrash G. A Novel HLA-A2 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target for Myeloid Leukemia. Blood 18(21), 2011. e-Pub 2011.
- Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, Quintanilla K, Armistead P, He H, Rodriguez-Cruz T, Clise-Dwyer K, Wieder E, Lizee G, Lu S, Molldrem JJ. Peripheral Tolerance to PR1 Is Maintained After Uptake of Soluble Proteinas-3 and Neutrophil Elastase. Blood 116(21), 2010. e-Pub 2010.
- Alatrash G, Mittendorf E, Sergeeva A, Sukhumalchandra P, Qiao N, Quintanilla K, Zhang M, Lu S, Clise-Dwyer K, Molldrem JJ. Soluble Inflammatory Mediators Proteinase-3 and Neutrophil Elastase Are Targeted by PR1-Specific Immunotherapy After Cellular Uptake and Cross Presentation of PR1 Peptide by Breast Cancer Cells. Blood 116(21), 2010. e-Pub 2010.
- Mittendorf E, Alatrash G, Qiao N, Sukhumalchandra P, Lu S, Quintanilla K, Clise-Dwyer K, Molldrem JJ. Cellular Uptake of Soluble Neutrophil Elastase Increases Cyclin E (CCNE) Isoform Expression and Significantly Augments Susceptibility of Breast Cancer Cells to Cytolysis by CCNE-Specific Cytotoxic T Lymphocytes. Blood 116(21), 2010. e-Pub 2010.
- Yang TH, Alatrash G, Clise-Dwyer K, Quintanilla K, Lu S, Molldrem JJ. Proteinase 3 Mediates Enzyme-Independent Reversible Inhibition of CD4 and CD8 T Cell Proliferation by Blocking G1-S Transition. Blood 116(21), 2010. e-Pub 2010.
- He H, Ishiyama K, Alatrash G, Kondo Y, Lu S, Molldrem JJ. T-cell immunity to two HLA-A2-restricted self-determinants of cyclin E may contribute to remission after stem cell transplantation. Blood 114(22), 2009. e-Pub 2009.
- Sergeeva A, Alatrash G, Clise-Dwyer K, Quintanilla KE, Lu S, Ma Q, Li D, Wang Y, You MJ, Molldrem JJ. Anti-PR1/HLA-A2 antibody (8FA, A TCR-mimic) mediates specific lysis of AML stem cells but not normal hematopoietic stem cells. Blood 114(22), 2009. e-Pub 2009.
- Liu X, Alexiou M, Martin-Orozco N, Chung Y, Nurieva R, Tian Q, Lu S, Kollia G, Graf D, Dong C. A critical role of BTLA in peripheral T cell tolerance induction. The Journal of Immunology 182, 2009. e-Pub 2009.
- Armistead P, Liang S, Lu S, van Bergen CAM, Falkenburg JHF, Molldrem JJ. Genomics as a tool for antigen discovery in allogeneic stem cell transplantation: Identification of the minor antigen T4A through donor/patient polymophism disparities (Poster). Blood 112(11):1332, 2008. e-Pub 2008.
- Sergeeva A, Lu S, Wygant JN, Alatrash G, Quintanilla K, Molldrem JJ. Direct visualization of PR1/HLA-A2 on the membrane of HLA-A2+CD13+CD33+ myeloid leukemia blasts by a novel monoclonal antibody (Poster). Blood 112(11):884, 2008. e-Pub 2008.
- Alatrash, G, Ono Y, Lu S, Sergeeva A, Sukhumalchandra P, Wang C, Wieder E, Molldrem JJ. Mistrafficking of primary granule proteins (PGPs) in leukemia simultaneously promotes PGP cross-priming and increases susceptibility to CTL killing. 2008 AACR Annual Proceedings, 2008. e-Pub 2008.
- Qazilbash MH, Wieder ED, Thall PF, Wang X, Rios R, Lu S, Kant S, Giralt S, Estey EH, Cortes J, Komanduri K, Champlin RE, Molldrem JJ. PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia (Oral Session). Blood 110(11), 2007. e-Pub 2007.
- Alatrash G, Ono Y, Lu S, Sergeeva A, Wang C, Wieder E, Molldrem JJ. Aberrant subcellular localization of azurophil granule proteins in myeloid leukemia favors peptide antigen presentation on MHC-I and susceptibility to killing by cytotoxic T lymphocytes. Blood 110(11), 2007. e-Pub 2007.
- Qazilbash MH, Wieder ED, Thall PF, Wang X, Rios R, Lu S, Kant S, Giralt S, Estey EH, Cortes J, Komanduri K, Champlin RE, Molldrem JJ. PR1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response and event-free survival (Oral Session). Blood 110(11), 2007. e-Pub 2007.
- Wang C, Ma Q, Wieder E, Lu S, Molldrem JJ. Ex vivo expansion of PR1-CTL elicited by autologous dendritic cells pulsed with PR1 peptide for adoptive immunotherapy of leukemia. The Journal of Immunology 178, 2007. e-Pub 2007.
- Rusakiewicz S, Kant S, Lizee G, Rabinovich B, Wieder E, Lu S, Hwu P, Molldrem J. CD8 T cells with high avidity TCR-ab specific for serine protease self-determinants for use in adoptive immunotherapy of human leukemia. The Journal of Immunology 178, 2007. e-Pub 2007.
- Ishiyama K, Kondo Y, Wieder E, Lu S, Molldrem J. HIgh avidity cyclin E-derived peptide-specific CTL contribute to induction of remission after stem cell transplantation. Biology of Blood and Marrow Transplantation 13(2):Supplement 1, page 32, 2007. e-Pub 2007.
- Ishiyama, K, Kondo Y, Wieder E, Lu S, Molldrem JJ. Aberrantly expressed neutrophil elastase (ELA2) in the nucleus and cytoplasm of acute lymphocytic leukemia (ALL) cells cleaves cyclin E (CCNE) into low-molecular-weight forms (LMWFs) yielding novel HLA-A2 restricted determinants. The Journal of Immunology 178, 2007. e-Pub 2007.
- Ishiyama K, Kondo Y, Wieder E, Lu S, Molldrem J. CTL with specificity for cyclin E self-antigen peptides contribute to remission after stem cell transplantation without associated graft-versus-host disease. Biology of Blood and Marrow Transplantation, 2007. e-Pub 2007.
- Ishiyama K, Kondo Y, Wieder E, Lu S, Molldrem JJ. Aberrantly expressed neutrophil elastase (ELA2) cleaves cyclin E (CCNE) in the nucleus and cytoplasm of acute lymphocytic leukemia yielding novel leukemia-associated antigens. Blood 108(11), 2006. e-Pub 2006.
- Ishiyama K, Kondo Y, Wieder E, Lu S, Molldrem J. High avidity PD-1 cyclin E-specific CTL contribute to leukemia remission and may be induced by epitope spread. The Journal of Immunology(A77):141.5, 2006. e-Pub 2006.
- Qazilbash MH, Rios R, Thall PF, Wang X, Wieder E, Lu S, Kant S, Giralt SA, Estey EH, Cortes J, Champlin RE, Komanduri KV, Molldrem JJ. PR1 vaccine after hematopoietic stem cell transplantation (Oral Presentation). Biology of Blood and Marrow Transplantation 12(2):Supplement 1, page 16, 2006. e-Pub 2006.
- Ono Y, Lu S, Sergeeva A, Wang C, Wieder E, Molldrem JJ. PR1 leukemia-associated antigen is cross-presented by B cells from soluble serum proteases (Poster). Blood 106(11):674a, 2005. e-Pub 2005.
- Ishiyama K, Wieder E, Lu S, Molldrem J. High avidity cyclin E-derived peptide-specific CTL contribute to induction of remission after stem cell transplantation without associated graft-versus-host disease (Poster). Blood 106(11):411a, 2005. e-Pub 2005.
- Kondo Y, Wieder E, Lu S, Molldrem JJ. High avidity cyclin E1-derived peptide-specific CTL kill lymphoid leukemia cells and cross-recognize a homologous cyclin E1-derived peptide (Poster). Biology of Blood and Marrow Transplantation 11(2):Supplement 1, page 61, 2005. e-Pub 2005.
- Qazilbash M, Wieder E, Rios R, Lu S, Kant S, Giralt S, Estey E, Thall P, de Lima M, Couriel D, Champlin R, Komanduri K, Molldrem J. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia (Oral Session). Blood 104(11):77a, 2004. e-Pub 2004.
- Kondo Y, Wieder E, Lu S, Molldrem J. High avidity cyclin E1-derived peptide-specific CTL kill lymphoid leukemia cells and cross-recognized a homologous cyclin E2-derived peptide. Blood 104(11):207b, 2004. e-Pub 2004.
- Ono Y, Kondo Y, Sergeeva A, Akande O, Sukhumalchandra P, Lu S, Wieder E, Molldrem J. Antigen cross-presentation allows the PR1 leukemia-associated antigen to be processed from both proteinase 3 and neutrophil elastase to prime T cells (Poster). Blood 104(11):886a, 2004. e-Pub 2004.
- Kondo Y, Lu S, Ding X, He Z, Wieder E, Molldrem JJ. Cyclin E2 peptide-specific CTL clone shows cross recognition of a homologous cyclin E1 peptide and kills lymphoid and myeloid leukemia cells (Poster). Blood 102(77):701a, 2003. e-Pub 2003.
- Wieder E, Kant S, Lu S, He Z, Molldrem JJ. PR1 peptide vaccination of myeloid leukemia patients induces PR1-specific CTL with high CCR7 expression (Poster). Blood 102(11):611a, 2003. e-Pub 2003.
- Ono Y, Kondo Y, Lu S, Molldrem JJ. The PR1 leukemia-associated antigen is endogeneously processed and presented from both proteinase 3 and neutrophil elastase and is recognized by T lymphocytes (Poster). Blood 102(11):694a, 2003. e-Pub 2003.
- Ono Y, St John L, Lu S, Wang C, Molldrem J. The leukemia-associated antigen PR1 is derived from both proteinase 3 and neutrophil elastase proteins (Poster). Biology of Blood and Marrow Transplantation 9(2):92-93, 2003. e-Pub 2003.
- Kondo Y, Lu S, Wang, C, Molldrem JJ. Two HLA-A2-restricted peptides from cyclin E1 and cyclin E2 elicit CTL that kill myeloid leukemia cell line. Biology of Blood and Marrow Transplantation 9(2):61, 2003. e-Pub 2003.
- Wang C, Lu S, Kinds Z, Sukhumalchandra P, Molldrem JJ. Dendritic cells cultured with interferon plus GM-CSF can be used to elicit PR1-specific CTL for adoptive immunotherapy (Poster). Biology of Blood and Marrow Transplantation 9(2):95, 2003. e-Pub 2003.
- Molldrem JJ, Wieder E, Kant S, Lu S, Rios R, Streicher H, Wang C, Giralt S, O Brien S, Cortes J, Champlin R Martin T. Peptide vaccination with PR1 elicits active T cell immunity that induces cytogenetic remission in acute myelogenous leukemia (Plenary Session). Blood 100(11):6a, 2002. e-Pub 2002.
- Kant S, Wieder E, Lu S, Kantarjian H, Talpaz M, Molldrem JJ. High affinity PR1-specific T cells participate in the maintenance of cytogenetic remission in interferon-sensitive chronic myelogenous leukemia patients off all therapy. Blood 100(11), 2002. e-Pub 2002.
- Kant S, Wieder E, Lu S, Molldrem J. Induction of a high affinity allogeneic PR1-specific CTL response is associated with cytogenetic remission after PR1 peptide vaccine. Blood 98(11):652a, 2001. e-Pub 2001.
- Lu S, Wieder E, He Z, Fernandez C, Giralt S, Champlin R, Molldrem JJ. Immunity to a novel myeloperoxidase peptide, proteinase 3 and the HA-1 minor antigen is present in AML patients that respond to nonablative stem cell transplant. Blood 98(11):855a, 2001. e-Pub 2001.
- Wieder E, Kant S, Lu S, He Z, Wang C, Huddleston H, O Brien S, Giralt S, Champlin R, Molldrem JJ. Effective specific immunity induced after PR1 peptide vaccination correlates with cytogenetic remission (Poster). Blood 98(11):407a, 2001. e-Pub 2001.
- Kuspa A, Lu S, Wang B, Chen G, Ibarra M, Shaulsky G. A demonstration of phenotyping in mixed cultures for use in large-scale analyses of mutant. The 2001 International Dictyostelium Conference, San Diego, CA, 2001. e-Pub 2001.
- Wessels DJ, Zhang H, Reynold J, Daniels K, Heid P, Lu S, Kuspa A, Shaulsky G, Loomis WF, Soll DR. The internal phosphodiesterase RegA is essential for the suppression of lateral pseudopods during dictyostelium chemotaxis. The 2000 International Dictyostelium Conference, Dundee, Scotland, 2000. e-Pub 2000.
- Kuspa A, Wang B, Souza G, Lu S. Control cAMP, PKA, and initiation of development in dictyostelium. 1997 International Dictyostelium Conference, Snowbird, UT, 1997. e-Pub 1997.
- Wang B, Lu S, Kuspa A. Evidence for a functional interaction between the regulatory subunit of PKA and the cytosolic regulator of adenylyl cyclase. 1996 International Dictyostelium Conference, Sendai, Japan, 1996. e-Pub 1996.
- Halberg R, Lu S, Kroos L. Role of sK RNA polymerase and SpoIIID protein in mother-cell gene regulation. 11th International Spores Conference, Woods Hole, MA, 1992. e-Pub 1992.
Patient Reviews
CV information above last modified March 25, 2026